Alpha Cognition (ACOG) Return on Capital Employed (2024 - 2025)
Alpha Cognition's (ACOG) quarterly Return on Capital Employed came in at 42.05% in Q4 2025, up 691.0% year-on-year from 5.32% in Q4 2024, and up 6.18% quarter-over-quarter from 44.82% in Q3 2025.
Alpha Cognition (ACOG) Return on Capital Employed (2024 - 2025) Analysis & Trends
Alpha Cognition's Return on Capital Employed history runs 2 years deep, the most recent figure standing at 42.05% for Q4 2025.
- On a quarterly basis, Return on Capital Employed rose 691.0% year-over-year to 42.05% in Q4 2025; TTM through Dec 2025 was 42.05%, a 691.0% increase from a year earlier, with the FY2025 full-year figure at 40.39%, up 1129.0% from the prior year.
- Return on Capital Employed improved to 42.05% in Q4 2025 per ACOG's latest filing, from 44.82% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 24.08% in Q1 2025 and bottomed at 2137.75% in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Alpha Cognition | 145.51 Mn | 79.41 Mn | 2.61 Mn | -42.05% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -42.05% |
| Sep 30, 2025 | -44.82% |
| Jun 30, 2025 | -33.32% |
| Mar 31, 2025 | -24.08% |
| Dec 31, 2024 | -48.97% |
| Sep 30, 2024 | -2,137.75% |